S241656 film-coated tablet 25mg

DRUG2 trials

Sponsors

Institut De Recherches Internationales Servier IRIS

Conditions

BRAF and Other Selected RAS/MAPK MutationsMalignancies with Documented KRASMyelodysplastic Syndrome /Acute Myeloid Leukemia (MDS/AML) or Chronic Myelomonocytic Leukemia (CMML)Patients with Acute Myeloid Leukemia (AML)

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Not yet recruitingCTIS2025-523474-16-00

Institut De Recherches Internationales Servier IRISMalignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations

Target: 75Updated: 2026-04-22

A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies

Not yet recruitingCTIS2025-525128-88-00

Institut De Recherches Internationales Servier IRISPatients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome /Acute Myeloid Leukemia (MDS/AML) or Chronic Myelomonocytic Leukemia (CMML)

Target: 17Updated: 2026-08-28